Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Evan Angelus"'
Autor:
Antonella Antignani, Lesley Mathews Griner, Rajarshi Guha, Nathan Simon, Matteo Pasetto, Jonathan Keller, Manjie Huang, Evan Angelus, Ira Pastan, Marc Ferrer, David J FitzGerald, Craig J Thomas
Publikováno v:
PLoS ONE, Vol 11, Iss 8, p e0161415 (2016)
The intersection of small molecular weight drugs and antibody-based therapeutics is rarely studied in large scale. Both types of agents are currently part of the cancer armamentarium. However, very little is known about how to combine them in optimal
Externí odkaz:
https://doaj.org/article/0b38042975494b8f8ea62a549061a7ac
Autor:
Christine Gummerson, Melvin Parasram, Teng Peng, John Picard, Peter Kahn, Evan Angelus, Shivani Bhatt, Adam De Havenon, Adam Jasne, Jessica Magid-Bernstein
Publikováno v:
Wednesday, April 26.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b62f5fd2e8b5e225d01ad4334d748e96
https://doi.org/10.1212/wnl.0000000000204097
https://doi.org/10.1212/wnl.0000000000204097
Autor:
Mitchell Ho, Evan Angelus, David J. FitzGerald, Evgeny Arons, Robert J. Kreitman, Antonella Antignani, Robert Sarnovsky, Emily Weiss
Publikováno v:
Antibody therapeutics. 2(1)
Background A feature of many B-cell tumors is a surface-expressed immunoglobulin (sIg). The complementarity-determining regions (CDRs) of the sIg, termed the ‘idiotype’, are unique to each tumor. We report on a phage selection strategy to generat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ebdae534e6df229c0403ab173d5e7e7
https://pubmed.ncbi.nlm.nih.gov/32166217
https://pubmed.ncbi.nlm.nih.gov/32166217
Autor:
Lesley A. Mathews Griner, Antonella Antignani, Rajarshi Guha, Matteo Pasetto, Craig J. Thomas, Manjie Huang, Marc Ferrer, Ira Pastan, Evan Angelus, Jonathan R. Keller, David J. FitzGerald, Nathan Simon
Publikováno v:
PLoS ONE, Vol 11, Iss 8, p e0161415 (2016)
PLoS ONE
PLoS ONE
The intersection of small molecular weight drugs and antibody-based therapeutics is rarely studied in large scale. Both types of agents are currently part of the cancer armamentarium. However, very little is known about how to combine them in optimal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d5786654e1ea4e21f4af025cda81688
https://doi.org/10.1371/journal.pone.0161415
https://doi.org/10.1371/journal.pone.0161415
Autor:
Mark Ferrer, Ira Pastan, Antonella Antignani, Nathan Simon, Evan Angelus, Manjie Huang, Lesley Mathews-Griner, David J. FitzGerald, Craig J. Thomas
Publikováno v:
Molecular Cancer Research. 14:A67-A67
Pseudomonas exotoxin (PE)-based immunotoxins (antibody-toxin fusion proteins) have produced frequent complete remissions in patients with hairy cell leukemia but far fewer responses in other cancers. PE and PE-immunotoxins kill cells via a pathway th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::201bebb5032e9eb05ad4a7d477f32163
https://doi.org/10.1158/1557-3125.metca15-a67
https://doi.org/10.1158/1557-3125.metca15-a67
Autor:
Lesley A. Mathews, Ira Pastan, Marc Ferrer, Antonella Antignani, Paul Shinn, Craig J. Thomas, David J. FitzGerald, Rajarshi Guha, Evan Angelus, Matteo Pasetto, Chris Choo
Publikováno v:
Cancer Research. 74:2907-2907
Recombinant immunotoxins, antibody-toxin fusion proteins, are therapeutic proteins designed as targeted anti-cancer agents. Clinical trials of immunotoxins directed to surface CD22 or mesothelin are ongoing with a 50% complete response rate in patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a3aead7ca292b6a4edde4f741a97862
https://doi.org/10.1158/1538-7445.am2014-2907
https://doi.org/10.1158/1538-7445.am2014-2907